- Home
- UPXI vs NTRB Comparison
UPXI vs NTRB Comparison
Compare UPXI & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UPXI | NTRB |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.8M | 72.6M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | UPXI | NTRB |
|---|---|---|
| Price | $1.04 | $5.80 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 3.4M | 42.9K |
| Earning Date | 05-15-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.49 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,811,345.00 | $2,036,651.00 |
| Revenue This Year | $118.99 | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.54 | $2.80 |
| 52 Week High | $7.75 | $8.63 |
Technical Indicators
Market Signals| Indicator | UPXI | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 53.14 | 72.84 |
| Support Level | $0.74 | $4.23 |
| Resistance Level | $1.17 | $6.41 |
| Average True Range (ATR) | 0.08 | 0.62 |
| MACD | -0.00 | 0.16 |
| Stochastic Oscillator | 31.97 | 77.98 |
Price Performance
Historical ComparisonAbout UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space via Solana. Geographically, the company generates the majority of its revenue from the United States.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.